• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    12/11/23 8:06:40 AM ET
    $BMEA
    $COGT
    $IONM
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email

    Gainers

    • Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 86.6% to $0.56 during Monday's pre-market session. The market value of their outstanding shares is at $11.6 million.
    • Assure Hldgs (NASDAQ:IONM) stock increased by 65.37% to $0.58. The company's market cap stands at $3.8 million.
    • Poseida Therapeutics (NASDAQ:PSTX) shares moved upwards by 25.94% to $3.98. The company's market cap stands at $380.5 million.
    • Protara Therapeutics (NASDAQ:TARA) shares rose 21.76% to $1.95. The company's market cap stands at $22.1 million.
    • Onconova Therapeutics (NASDAQ:ONTX) stock rose 15.51% to $0.73. The market value of their outstanding shares is at $15.3 million.
    • OneMedNet (NASDAQ:ONMD) shares increased by 14.28% to $1.36. The market value of their outstanding shares is at $43.8 million.

    Losers

    • Cogent Biosciences (NASDAQ:COGT) stock declined by 26.5% to $6.35 during Monday's pre-market session. The company's market cap stands at $546.8 million.
    • X4 Pharmaceuticals (NASDAQ:XFOR) stock fell 23.89% to $0.67. The market value of their outstanding shares is at $112.0 million.
    • Vapotherm (NYSE:VAPO) stock decreased by 21.83% to $1.54. The company's market cap stands at $9.4 million.
    • Purple Biotech (NASDAQ:PPBT) stock declined by 15.95% to $0.93. The market value of their outstanding shares is at $22.8 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares declined by 14.7% to $0.27. The company's market cap stands at $2.5 million.
    • Biomea Fusion (NASDAQ:BMEA) shares fell 12.38% to $14.8. The market value of their outstanding shares is at $528.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMEA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMEA
    $COGT
    $IONM
    $KTTA

    CompanyDatePrice TargetRatingAnalyst
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Protara Therapeutics Inc.
    $TARA
    1/7/2026$24.00Overweight
    Piper Sandler
    X4 Pharmaceuticals Inc.
    $XFOR
    12/5/2025$10.00Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$40.00Hold → Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    Cogent Biosciences Inc.
    $COGT
    10/16/2025$16.00Hold
    Stifel
    Cogent Biosciences Inc.
    $COGT
    9/3/2025$30.00Strong Buy
    Raymond James
    Biomea Fusion Inc.
    $BMEA
    8/28/2025$5.00Buy
    Jefferies
    More analyst ratings

    $BMEA
    $COGT
    $IONM
    $KTTA
    SEC Filings

    View All

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    2/20/26 5:00:53 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

    SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

    2/17/26 4:33:46 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.

    SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    2/17/26 4:30:31 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

    Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva

    2/23/26 5:05:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Thursday, February 26 at 2:40 pm ET.TD Cowen 46th Annual Health Care Conference. A fireside chat will take place on Tuesday, March 3 at 2:30 pm ET in Boston. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The

    2/19/26 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biomea Fusion to Participate at Upcoming Investor Conferences

    SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.The Citizens Life Sciences Conference: Biomea will present at 2:50 PM (EDT) on March 10, 2026, in Miami, FL. Company management will also meet with investors in one-on-one meetings during the confer

    2/19/26 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Erdtmann Rainer M decreased direct ownership by 21% to 572,427 units (SEC Form 5)

    5 - Biomea Fusion, Inc. (0001840439) (Issuer)

    2/6/26 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:13 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:15 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BMEA
    $COGT
    $IONM
    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Protara Therapeutics with a new price target

    Piper Sandler initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/26 9:14:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on X4 Pharmaceuticals with a new price target

    Stifel resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    12/5/25 8:46:35 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Financials

    Live finance-specific insights

    View All

    TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

    Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva

    2/23/26 5:05:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $COGT
    $IONM
    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/18/24 6:01:42 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care